Growth failure is a common problem in HIV-infected children. The extent to which this growth failure could be reversed after the children receive antiretroviral therapy (ART) is not known. This study assessed the incidence of growth failure in HIV-infected Thai children, impact of ART on growth, and the predictors of growth reversal after initiating ART. Growth parameters and other characteristics were extracted from the database of a prospective cohort of HIV-infected children (age 15 years) who were enrolled to initiate non-nucleoside reverse transcriptase inhibitor-based ART between August 2002 and May 2007. Body weight and height measurements, CD4 cell counts, plasma HIV RNA levels were collected at baseline and 24-week intervals. A total of 225 HIV-infected children were included, 116 (51%) were males. The median age at baseline was 7.4 years (interquartile range [IQR] 5.2-9.8). Fifty-three percent were in Centers for Disease Control and Prevention (CDC) category C and 54% had CD4 percentage 5 or less. The mean (standard deviation [SD]) of baseline weight-for-age (WAZ) and height-forage (HAZ) z-scores were À2.02 (1.17) and À2.22 (1.51). The median follow-up time was 216 weeks (IQR 120-240). The cumulative probability of growth reversal among the 179 subjects with growth failure at entry was 58% (95% confidence interval [CI] 49-67) at week 240. In a multivariate Cox regression model, higher entry WAZ ( p < 0.001) and HAZ ( p < 0.001), use of a nevirapine-based regimen (compared to efavirenz, p ¼ 0.027) and larger CD4% gains to week 48 ( p < 0.001) were significant predictors of growth reversal after initiating ART. NNRTI-based ART leads to a substantial improvement in growth of HIV-infected children. Initiation of ART before the children developed growth failure should be encouraged.
Introduction

G
rowth failure is one of the most common presenting symptoms among HIV-infected children. It may be caused by HIV infection itself, other opportunistic infections, inadequate nutritional intake or other HIV-related factors. The growth of HIV-infected children is much slower when compared to that of uninfected children. This growth failure dramatically worsens with age. 1 Studies have shown that the growth velocity in HIV-infected children is significantly related to their survival. 2, 3 In the last decade, highly active antiretroviral treatment (ART) has significantly improved the virologic, immunologic, and clinical outcomes in both adults and children. [4] [5] [6] Many studies from developed countries using protease inhibitor (PI)-based ART regimen showed an improvement in growth of HIV-infected children after initiating ART. [7] [8] [9] Studies from Kenya and Uganda also showed significant improvements in weight and height as well as immunological and virologic parameters of perinatally HIVinfected children after ART initiation. 10, 11 We had reported on the efficacy of ART in children participating in Thailand's national access to antiretroviral program. 4, 5 In the present study, we reported the incidence of growth failure in HIVinfected children, impact of ART on growth, and the predictors of growth reversal after initiating ART.
composed of HIV-infected treatment-naïve children (age 15 years) enrolled between August 2002 and May 2007 to start ART at Chiang Mai University Hospital, Chiang Mai Provincial Hospital, Lamphun Provincial Hospital, and Sanpatong District Hospital in northern Thailand. The study was approved by the research ethics committee of Chiang Mai University. Written informed consent was obtained from each child's parent or guardian prior to enrollment. All children received a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART composed of two nucleoside reverse transcriptase inhibitors (lamivudine and either stavudine or zidovudine) plus either nevirapine (NVP) or efavirenz (EFV). The data were frozen and analyzed on May 31, 2008.
Measurements
Data at week 0 (start of treatment), 24, 48, and every 24 weeks thereafter were extracted. CD4 cell counts were assessed using FACS Count machine (Becton-Dickinson, Mountain View, CA). Plasma HIV RNA level was measured by using the Roche Ultrasensitive Amplicor assay, version 1.5 (Roche Diagnostics, Indianapolis, IN). Weight and height measurements were converted to age-and gender-adjusted zscores (WAZ and HAZ) based on normal ranges for healthy Thai children. 12 In this study, a child is defined as having growth failure if his or her WAZ less than À1.5 and=or HAZ less than À1.5. In a child with growth failure, growth reversal is defined as having both the WAZ and HAZ À1.5 or greater. Viral suppression was defined as plasma HIV RNA level less than 50 copies per milliliter.
Statistical analysis
Continuous variables were presented as mean (standard deviation [SD]) or median (interquartile range [IQR]) as appropriate. Categorical variables were presented as proportion. The paired t test was used to compare growth parameters of each subject at various time points. The predictors of growth reversal were analyzed utilizing Cox regression analysis. Kaplan-Meier analysis was used to estimate the cumulative probability of growth reversal. In this analysis, those who died, were lost to follow-up or changed their regimens as a result of treatment failure were censored at the time of the event. A two-sided p value of <0.05 was considered significant. Data was analyzed by using SPSS version 14.0 (SPSS Inc., Chicago, IL).
Results
Characteristics of the study population
Two hundred twenty-five HIV-infected children were included in the study. Their baseline characteristics before receiving ART are shown in Table 1 . The mean age was 7.2 years (SD 3.5). Fifty-three percent were in Centers for Disease Control and Prevention (CDC) category C while 54% had CD4 percentage 5 or less. Seventy-four percent had plasma HIV RNA level greater than 5 log 10 copies per milliliter. Eighty percent of children had growth failure. The median follow-up time was 216 weeks (IQR 120-240). Ten children died from HIV-related illness at the median time of 39 weeks (IQR 19-78) whereas 6 had moved to other hospitals or were lost to follow-up. There were 12 children who needed to switch from NNRTI-to PI-based regimen at a median time of 73 weeks (IQR 59-83) due to virologic failure: 10 from the NVP-based and 2 from the EFV-based groups.
Change in growth parameters
The change in growth parameters from baseline is shown in Table 2 . The mean WAZ and HAZ at week 24 and week 48, respectively, and at every time point thereafter were statistically different from the mean WAZ and HAZ at baseline.
At baseline 179 children (80%) of the children had growth failure (Table 1) . Among these 179 children, the cumulative probability of growth reversal at various time points after ART initiation was shown in Figure 1 . The cumulative probability of growth reversal at week 240 was 58% (n ¼ 179, 95% confidence interval [CI] 49-67). A sensitivity analysis was performed in which deaths, loss to follow-up, and treatment change were not censored. The result of this sensitivity analysis did not affect the conclusion.
Virologic and immunologic outcomes
Sixty-five percent of all children had CD4 percentage 15 or more at week 48 after ART initiation while viral suppression was seen in 69%. Among the 179 children who had growth failure at baseline, 72% had viral suppression and 62% had CD4 percentage 15 or more at week 48.
Predictors of growth reversal among children who had growth failure at baseline
From multivariate Cox regression analysis, among 179 children who had baseline growth failure, predictors for growth reversal were baseline WAZ and HAZ, ART regimen 1068 AURPIBUL ET AL.
as well as CD4 gain at week 48 after starting ART (Table 3 ). In the multivariate analysis model, for each increase of 0.5 units in baseline WAZ and HAZ, there were a 33% and 47% increase in the risk of achieving growth reversal, respectively, ( p < 0.001). In children who received nevirapine-based regimen, there was a 72% increase in the risk of achieving reversal compared to those who received EFV-based regimen ( p ¼ 0.027), and for each 5% increase in CD4 percentage gain at week 48 after ART, there was a 35% increase the risk of achieving growth reversal ( p < 0.001).
Discussion
Growth failure, or failure to thrive, is a common presentation in HIV-infected young children. However, no consensus has been reached concerning the specific anthropometrical criteria to define growth failure. For examples, some authors define growth failure as height or weight less than the third to fifth percentiles for age on more than one occasion using the standard growth charts of normal healthy children of the same nationality. In this study, we define growth failure as having WAZ less than À1.5 and=or HAZ less than À1.5. The Z-score of À1.5 is equal to the 6.7th percentile. We believe that using a combination end point of weight and height and a cutoff at 6.7th percentile is another acceptable means of defining growth failure.
In this study, we documented that NNRTI-based ART had reversed growth failure in a substantial number of HIVinfected children. A statistically significant improvement was seen within the first year after ART initiation; at week 24 and week 48 for WAZ and HAZ, respectively. While the mean WAZ returned to À1.5 or greater at week 48, it was not until week 144 when the mean of HAZ returned to À1.5 or greater. High baseline WAZ or HAZ, receiving NVP-based ART regimen, and CD4 cell percentage gain at week 48 after starting ART are predictors for growth reversal.
Studies from India, Cambodia, Tanzania, Kenya, and South Africa that intended to show the efficacy of NNRTI-based ART in terms of immunologic and virologic responses also demonstrated improvement in growth. 10, [13] [14] [15] [16] [17] [18] Similarly, studies from developed countries such as The Netherlands, United States, and Spain where PI-based regimen was mainly used also showed improvement in growth after starting ART. [7] [8] [9] Study from a large pediatric cohort in the United States and Uganda found that significant improvement in weight preceded that in height. 8, 11 However, the rate and degree to which improvement in growth occurred could not be compared among these studies because of the different criteria used to define growth failure and the difference in severity of HIV infection at the time ART was started. In our study in which 53% of the children were in CDC disease category C and 54% had CD4 percentage 5% or less at baseline, the cumulative probability of growth reversal was only 58% at week 240 after ART initiation. In countries where CD4 measurement is not available, the current World Health Organization (WHO) guideline recommends initiating ART for HIV-infected children with low weight-for-age (WAZ À2) not explained by poor or inadequate feeding and=or other infections, and not adequately responding to standard management. 19 Thus, following the WHO guideline can be expected to result in the rate and degree of improvement in growth similar to that of our study (Table 2) . Children with WAZ ! À1.5
(31)
91 (42) 104 (48) 109 (52) 106 (56) 106 (60) 105 (64) 94 (63) 97 (67) 82 (65) 67 (66) Children with HAZ ! À1.5
64 (30) 80 (37) 82 (39) 86 (45) 84 (48) 93 (56) 81 (54) 81 (56) 70 (55) 51 (50) Children with WAZ and HAZ ! À1.5
46 (20) 54 (25) 69 (32) 74 (36) 78 (41) 75 (43) 87 (53) 76 (51) 78 (54) 66 (52) 47 ( The reason why children who received NVP-based regimen had a higher probability of growth reversal compared to EFV-based regimen is unclear. Our study was done in an observational cohort where the choice of ART regimen was made by the child's pediatrician. Because of the paucity of clinical data of EFV in children aged less than 3 years, most of the children less than 3 years of age in our study received the NVP-based regimen. The U.S. study showed that children aged less than 2 years had more rapid growth change after starting ART when compared to older children. 8 In addition, EFV-based ART regimen is known to be related to higher incidence of metabolic derangement, e.g., dyslipidemia, gynecomastia, than NVP-based. 20 More studies are needed to confirm this finding and also to explain the pathogenesis.
Our study was done in a large long-term homogenous prospective cohort where all children received NNRTI-based ART as recommended by WHO. This provided us an opportunity to assess the long-term effects of antiretroviral therapy on growth in these children. Yet our study has some limitations because there were no data on nutritional assessment and socioeconomic status that might affect the growth of HIVinfected children.
In conclusion, NNRTI-based ART leads to a substantial improvement in growth of HIV-infected children. Maintaining normal growth should be one of the objectives in providing treatment and care of HIV-infected children. More efforts should be made to initiate ART treatment early in resourcelimited countries before the children develop severe growth retardation to provide an opportunity for growth reversal after starting ART. Nutritional assessment and appropriate intervention should also be considered as one of the components of comprehensive treatment and care for HIV-infected children.
